Related Experiment Video

Updated: Aug 31, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Antiatherogenic properties of metformin: the experimental evidence

J C Mamputu1, N F Wiernsperger, G Renier

  • 1CHUM Research Center, Notre-Dame Hospital, Laboratory of Vascular Immunology, University of Montréal, Québec, Canada.

Diabetes & Metabolism
|September 23, 2003
PubMed

Insights

Metformin, a type 2 diabetes drug, shows antiatherogenic properties by improving cardiovascular risk factors and reducing complications. This review covers evidence supporting its role in preventing atherosclerosis in diabetic patients.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a primary cause of death in type 2 diabetes patients.
  • Type 2 diabetes and atherosclerosis share a strong link, suggesting anti-diabetic drugs may impact the disease process.
  • Metformin is a common hypoglycemic agent for type 2 diabetes.

Purpose of the Study:

  • To review experimental evidence on metformin's antiatherogenic effects.
  • To explore how metformin influences cardiovascular risk factors in diabetes.

Main Methods:

  • In vivo and in vitro experimental data were summarized.
  • Evidence on metformin's effects on atherosclerosis and risk factors was analyzed.

Main Results:

  • Metformin demonstrates favorable effects on multiple cardiovascular risk factors.
  • The drug has been shown to reduce macrovascular complications in obese type 2 diabetic patients.
  • Experimental studies support metformin's antiatherogenic properties.

Conclusions:

  • Metformin possesses antiatherogenic properties beneficial for type 2 diabetes patients.
  • The drug's effects on cardiovascular risk factors contribute to its protective role against atherosclerosis.
  • Further investigation into metformin's mechanisms in preventing atherosclerosis is warranted.

More Related Videos

Fixation and Operational Method for Abdominal Massage in T2DM Mice05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...